Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Receivables (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Change in Receivables for 6 consecutive years, with $870000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 38.03% to $870000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$485000.0 through Dec 2025, down 142.96% year-over-year, with the annual reading at -$485000.0 for FY2025, 142.96% down from the prior year.
  • Change in Receivables hit $870000.0 in Q4 2025 for Insight Molecular Diagnostics, up from -$254000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.9 million in Q1 2025 to a low of -$3.0 million in Q2 2025.
  • Historically, Change in Receivables has averaged $116950.0 across 5 years, with a median of $73000.0 in 2022.
  • Biggest five-year swings in Change in Receivables: surged 6585.71% in 2024 and later tumbled 3884.21% in 2025.
  • Year by year, Change in Receivables stood at $405000.0 in 2021, then plummeted by 94.57% to $22000.0 in 2022, then decreased by 4.55% to $21000.0 in 2023, then soared by 6585.71% to $1.4 million in 2024, then tumbled by 38.03% to $870000.0 in 2025.
  • Business Quant data shows Change in Receivables for IMDX at $870000.0 in Q4 2025, -$254000.0 in Q3 2025, and -$3.0 million in Q2 2025.